Polyphor have successfully completed a Phase I trial of CXCR4 inhibitor POL6326 for use in hematopoietic stem cell (HSC) transplantation and leukemia.
Filed under: Uncategorized | Tagged: CXCR4, POL-6326, POL6326, Polyphor | Leave a Comment »
Tags
5-HT1A 5-HT2 5-HT2A 5-HT3 5-HT4 5-ht6 5HT1A 5HT1D 5HT2 5HT2A 5HT3 5HT4 5ht6 agonist Angiotensin II AT1 antagonist Astrazeneca Beta 2 adrenoceptor Cannabinoid CB1 Daiichi-Sankyo Dopamine Dopamine D2 Fentanyl ghrelin GlaxoSmithkline GLP-1 gpcr GSK Histamine H1 Licensing Lilly Merck Muscarinic Opioid Opioid mu phase I phase II phase III Preclinical regulatory Research Sanofi-Aventis TRPV1 Vanilloid
Calendar
Blogroll
Blog at WordPress.com. Theme: Digg 3 Column by WP Designer
